These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 33670839)

  • 1. Changes in Glutathione Content in Liver Diseases: An Update.
    Vairetti M; Di Pasqua LG; Cagna M; Richelmi P; Ferrigno A; Berardo C
    Antioxidants (Basel); 2021 Feb; 10(3):. PubMed ID: 33670839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Glutathione in Selected Viral Diseases.
    Wróblewska J; Wróblewski M; Hołyńska-Iwan I; Modrzejewska M; Nuszkiewicz J; Wróblewska W; Woźniak A
    Antioxidants (Basel); 2023 Jun; 12(7):. PubMed ID: 37507865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutathione: Pharmacological aspects and implications for clinical use in non-alcoholic fatty liver disease.
    Santacroce G; Gentile A; Soriano S; Novelli A; Lenti MV; Di Sabatino A
    Front Med (Lausanne); 2023; 10():1124275. PubMed ID: 37035339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutathione synthesis.
    Lu SC
    Biochim Biophys Acta; 2013 May; 1830(5):3143-53. PubMed ID: 22995213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decoding cell death signals in liver inflammation.
    Brenner C; Galluzzi L; Kepp O; Kroemer G
    J Hepatol; 2013 Sep; 59(3):583-94. PubMed ID: 23567086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-alcoholic fatty liver disease is associated with greater risk of 30-day hospital readmission in the United States (U.S.).
    Paik JM; Eberly KE; Kabbara K; Harring M; Younossi Y; Henry L; Verma M; Younossi ZM
    Ann Hepatol; 2023; 28(4):101108. PubMed ID: 37088421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
    Serviddio G; Bellanti F; Vendemiale G
    Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deficiency in glutathione synthesis and reduction contributes to the pathogenesis of colitis-related liver injury.
    Wang L; Han R; Zang K; Yuan P; Qin H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Mar; 47(3):271-279. PubMed ID: 35545319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis.
    Mohs A; Otto T; Schneider KM; Peltzer M; Boekschoten M; Holland CH; Hudert CA; Kalveram L; Wiegand S; Saez-Rodriguez J; Longerich T; Hengstler JG; Trautwein C
    J Hepatol; 2021 Mar; 74(3):638-648. PubMed ID: 33342543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving survival in patients with hepatocellular carcinoma related to chronic hepatitis C and B but not in those related to non-alcoholic steatohepatitis or alcoholic liver disease: a 20-year experience from a national programme.
    Hassan I; Gane E
    Intern Med J; 2019 Nov; 49(11):1405-1411. PubMed ID: 30908822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alkylating Agent-Induced NRF2 Blocks Endoplasmic Reticulum Stress-Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis.
    Zanotto-Filho A; Masamsetti VP; Loranc E; Tonapi SS; Gorthi A; Bernard X; Gonçalves RM; Moreira JC; Chen Y; Bishop AJ
    Mol Cancer Ther; 2016 Dec; 15(12):3000-3014. PubMed ID: 27638861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxygen free radicals and glutathione in hepatic ischemia/reperfusion injury.
    Stein HJ; Oosthuizen MM; Hinder RA; Lamprechts H
    J Surg Res; 1991 Apr; 50(4):398-402. PubMed ID: 2020191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Environmental toxicity, redox signaling and lung inflammation: the role of glutathione.
    Biswas SK; Rahman I
    Mol Aspects Med; 2009; 30(1-2):60-76. PubMed ID: 18760298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study.
    Marot A; Henrion J; Knebel JF; Moreno C; Deltenre P
    PLoS One; 2017; 12(10):e0186715. PubMed ID: 29077714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
    Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB
    Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular pathogenesis: Connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma.
    Tian Z; Xu C; Yang P; Lin Z; Wu W; Zhang W; Ding J; Ding R; Zhang X; Dou K
    Front Immunol; 2022; 13():984728. PubMed ID: 36189208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Patterns and Outcome of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
    Ahn SY; Kim SB; Song IH
    Can J Gastroenterol Hepatol; 2020; 2020():4873875. PubMed ID: 32566546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Glutathione Metabolism in Chronic Illness Development and Its Potential Use as a Novel Therapeutic Target.
    Hristov BD
    Cureus; 2022 Sep; 14(9):e29696. PubMed ID: 36321012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutathione and Glutaredoxin-Key Players in Cellular Redox Homeostasis and Signaling.
    Chai YC; Mieyal JJ
    Antioxidants (Basel); 2023 Aug; 12(8):. PubMed ID: 37627548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The glutathione system and the related thiol network in Caenorhabditis elegans.
    Ferguson GD; Bridge WJ
    Redox Biol; 2019 Jun; 24():101171. PubMed ID: 30901603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.